Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, BioCryst Pharmaceuticals Inc maintains a gross margin of 98.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 18.56%, while the net margin is 8.09%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BCRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BCRX competes directly with industry leaders such as KMDA and NVAX. With a market capitalization of $1.68B, it holds a leading position in the sector. When comparing efficiency, BCRX's gross margin of 98.63% stands against KMDA's 42.04% and NVAX's 69.49%. Such benchmarking helps identify whether BioCryst Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
